3077-51-8

Basic information

• Product Name: 5-methyl L-2-aminoglutarate hydrochloride
• Synonyms: 5-methyl L-2-aminoglutarate hydrochloride;Glutamic acid γ-methyl ester·hydrochloride;γ-Methyl glutamate hydrochloride;(S)-2-Amino-5-methoxy-5-oxopentanoic acid hydrochloride;(2S)-2-amino-5-methoxy-5-oxopentanoic acid hydrochloride
• CAS NO: 3077-51-8
• Molecular Formula: C₆H₁₁NO₄*ClH
• Molecular Weight: 197.61678
• EINECS: 221-365-4
• Mol File: 3077-51-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 316.1°C at 760 mmHg
• Flash Point: 145°C
• Appearance: /
• Vapor Pressure: 8.95E-05mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-methyl L-2-aminoglutarate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl L-2-aminoglutarate hydrochloride(3077-51-8)
• EPA Substance Registry System: 5-methyl L-2-aminoglutarate hydrochloride(3077-51-8)

Safety Data

• Hazardous Substances Data: 3077-51-8(Hazardous Substances Data)

Usage

General Description

5-methyl L-2-aminoglutarate hydrochloride is a compound that belongs to the family of amino acids, specifically glutamic acid derivatives. It is a synthetic chemical with a molecular formula of C6H12NO5?HCl, and it is commonly used in the field of biochemistry and pharmaceutical research. 5-methyl L-2-aminoglutarate hydrochloride has been studied for its potential benefits in various physiological processes, especially those related to metabolism and energy production. It is also used as a building block for the synthesis of other biologically active compounds and as a standard for analytical testing. Overall, 5-methyl L-2-aminoglutarate hydrochloride plays a significant role in the development of new drugs and in understanding the biochemical pathways in living organisms.

InChI:InChI=1/C6H11NO4.ClH/c1-11-5(8)3-2-4(7)6(9)10;/h4H,2-3,7H2,1H3,(H,9,10);1H

Upstream product

• 67-56-1 methanol 
• 56-86-0 L-glutamic acid 
• 75-77-4 chloro-trimethyl-silane 

Downstream Products

• 4510-09-2 N-benzyloxycarbonyl-L-glutamic acid-5-hydrazide 
• 79640-72-5 L-glutamic acid 1-tert-butyl ester 5-methyl ester 
• 118545-50-9 α-tert-butyl γ-methyl N-trityl-L-glutamate 
• 118545-54-3 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-(2S)-pentanoate 
• 125089-94-3 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-(2S)-hexanoate 
• 118545-51-0 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-(2S)-heptanoate 
• 118545-53-2 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-5-methyl-(2S)-hexanoate 
• 118545-55-4 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-6-methyl-(2S)-heptanoate 
• 125089-93-2 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-(2S)-octanoate 
• 118545-52-1 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-5-phenyl-(2S)-pentanoate 
• 125089-95-4 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-5-(4-methoxyphenyl)-(2S)-hexanoate 
• 118545-56-5 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-5-(4-nitrophenyl)-(2S)-pentanoate 
• 1459764-32-9 C₃₈H₃₆N₄O₁₂ 
• 1459764-59-0 C₃₂H₄₂N₄O₁₂ 

Relevant articles and documents

Syntheses of Enantiopure 1,2-Ethylenediamines with Tethered Secondary Amines of the Formula H 2NCH 2CH[(CH 2) nNHMe]NH 2(n = 1-4) from α-Amino Acids: New Agents for Asymmetric Catalysis

Tris(hydrochloride) adducts of the title compounds-are prepared from the inexpensive α-amino acids H 2 N(C=O)CH 2 CH(NH 2)CO 2 H, HO(C=O)(CH 2) n ′ CH(NH 2)CO 2 H (n ′ = 1, 2), and H2 N(CH 2) 4 CH(NH 2)CO 2 H, respectively (steps/overall yield = 5/32, 7/30, 7/33, 5/38). The NH 2 group that is remote from the secondary amine is installed via BH 3 reduction of an amide [-(C=O)NR 2[ derived?-from an α-amino carboxylic acid. The MeNHCH 2 units are introduced by BH 3 reductions of alkyl carbamate [RO(C=O)NHCH 2-; R = Et, t-Bu] or amide [MeHN(C=O)-] moieties.

SERINE REPLACEMENT POLYMYXIN ANALOGUES USEFUL AS ANTIBIOTIC POTENTIATORS

The disclosure provides compounds of the formula I or a tautomer thereof, or a pharmaceutically acceptable salt of either of the foregoing. The variables R1 and R2 are defined in the disclosure. The disclosure further includes pharmaceutical compositions comprising a compound of formula I together with at least one pharmaceutically acceptable carrier. The disclosure also includes a method of sensitizing bacteria to an antibacterial agent, comprising administering a therapeutically effective amount of the antibacterial agent and a compound of formula I to a patient infected with the bacteria, simultaneously or sequentially.

Diaminodiacid-based solid-phase synthesis of peptide disulfide bond mimics

The antimicrobial peptide tachyplesin I was used as a model to apply the title strategy, which was developed for the preparation of peptidic macrocycles with double disulfide surrogates. The folding and activity of the tachyplesin I analogues were found to be sensitive to the structure of the disulfide surrogates, thus underlining the necessity of a flexible synthetic route for generating disulfide bond surrogates with high structural diversity. Copyright